 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || COVID-19 mRNA vaccine / CanSino
Clinical, P1 data, Journal: Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults. (Pubmed Central) - Nov 27, 2023
P1
Adverse reactions in the low-dose and high-dose groups were mainly of severity grade 1 or 2, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.
- || COVID-19 mRNA vaccine / CanSino
Trial primary completion date: Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - Oct 23, 2023
P2, N=150, Active, not recruiting, Sponsor: CanSino Biologics Inc.
These findings support further development of this vaccine. Trial primary completion date: Jul 2023 --> Dec 2023
- || COVID-19 mRNA vaccine / CanSino
Enrollment change, Trial completion date, Trial primary completion date: Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - Oct 23, 2023
P1, N=150, Active, not recruiting, Sponsor: CanSino Biologics Inc.
Trial primary completion date: Jul 2023 --> Dec 2023 N=43 --> 150 | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Nov 2023
- ||| COVID-19 mRNA vaccine / CanSino
Enrollment closed, Enrollment change: Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - Jun 15, 2023
P2, N=150, Active, not recruiting, Sponsor: CanSino Biologics Inc.
N=43 --> 150 | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Nov 2023 Recruiting --> Active, not recruiting | N=300 --> 150
- || COVID-19 mRNA vaccine / CanSino
Enrollment closed, Enrollment change, Trial primary completion date: Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - Jun 15, 2023
P1, N=43, Active, not recruiting, Sponsor: CanSino Biologics Inc.
Recruiting --> Active, not recruiting | N=300 --> 150 Recruiting --> Active, not recruiting | N=80 --> 43 | Trial primary completion date: May 2023 --> Aug 2023
- |||| COVID-19 mRNA vaccine / CanSino
Enrollment open: Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - Jul 11, 2022
P2, N=300, Recruiting, Sponsor: CanSino Biologics Inc.
Recruiting --> Active, not recruiting | N=80 --> 43 | Trial primary completion date: May 2023 --> Aug 2023 Not yet recruiting --> Recruiting
- ||| COVID-19 mRNA vaccine / CanSino
Enrollment open: Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - Jul 6, 2022
P1, N=80, Recruiting, Sponsor: CanSino Biologics Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, COVID-19 mRNA vaccine / CanSino
Journal: mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern. (Pubmed Central) - Jun 9, 2022
The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high level cross-reactive neutralization for Beta, original, Delta and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
- ||||| COVID-19 mRNA vaccine / CanSino
New P2 trial: Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - May 12, 2022
P2, N=300, Not yet recruiting, Sponsor: CanSino Biologics Inc.
- ||| COVID-19 mRNA vaccine / CanSino
New P1 trial: Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - May 12, 2022
P1, N=80, Not yet recruiting, Sponsor: CanSino Biologics Inc.